MCID: PTT006
MIFTS: 53

Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Pituitary Adenoma

MalaCards integrated aliases for Pituitary Adenoma:

Name: Pituitary Adenoma 12 29 55 15 73
Pituitary Neoplasms 44 73
Adenoma of the Pituitary Gland 12
Pituitary Adenomas 37
Adenoma, Pituitary 40

Classifications:



External Ids:

Disease Ontology 12 DOID:3829
MeSH 44 D010911
NCIt 50 C3329
KEGG 37 H01102

Summaries for Pituitary Adenoma

Disease Ontology : 12 An adenoma that is located in the pituitary gland.

MalaCards based summary : Pituitary Adenoma, also known as pituitary neoplasms, is related to functionless pituitary adenoma and thyroid cancer, nonmedullary, 1. An important gene associated with Pituitary Adenoma is MIR16-1 (MicroRNA 16-1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and ErbB signaling pathway. The drugs Hydrocortisone acetate and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and liver.

Wikipedia : 76 Pituitary adenomas are tumors that occur in the pituitary gland. Pituitary adenomas are generally... more...

Related Diseases for Pituitary Adenoma

Diseases in the Pituitary Adenoma family:

Pituitary Adenoma 1, Multiple Types Pituitary Adenoma 5, Multiple Types
Pituitary Adenoma 3, Multiple Types

Diseases related to Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 functionless pituitary adenoma 33.6 HOTAIR MEG3
2 thyroid cancer, nonmedullary, 1 30.4 H19 HOTAIR MALAT1 MEG3 MIR15A
3 osteogenic sarcoma 30.1 CCAT2 H19 HOTAIR MALAT1 MEG3
4 glioma 30.0 CCAT2 H19 HOTAIR MALAT1 MEG3 MIR15A
5 prostate cancer 29.9 CCAT2 H19 HOTAIR MALAT1 MEG3 MIR149
6 glioblastoma 29.8 H19 HOTAIR MALAT1 MEG3 MIR128-1 MIR197
7 melanoma 29.4 H19 HOTAIR MALAT1 MEG3 MIR128-1 MIR149
8 lung cancer 29.3 CCAT2 GADD45G H19 HOTAIR MALAT1 MEG3
9 breast cancer 29.0 CCAT2 H19 HOTAIR MALAT1 MEG3 MIR128-1
10 pituitary adenoma, prolactin-secreting 12.7
11 acth-secreting pituitary adenoma 12.7
12 familial isolated pituitary adenoma 12.6
13 pituitary adenoma 4, acth-secreting 12.6
14 pituitary adenoma 1, multiple types 12.6
15 pituitary adenoma 5, multiple types 12.6
16 pituitary adenoma 2, growth hormone-secreting 12.5
17 pituitary adenoma 3, multiple types 12.5
18 growth hormone secreting pituitary adenoma 12.4
19 functioning pituitary adenoma 12.4
20 aip-related familial isolated pituitary adenomas 12.3
21 non-functioning pituitary adenoma 12.3
22 silent pituitary adenoma 12.2
23 null pituitary adenoma 12.1
24 acroleukopathy, symmetric 11.7
25 chromophobe adenoma 11.7
26 acromegaly 11.5
27 conn's syndrome 11.5
28 pituicytoma 11.5
29 chiasmal syndrome 11.4
30 adenoma 11.3
31 tsh producing pituitary tumor 11.3
32 somatomammotropinoma 11.3
33 gastrointestinal defects and immunodeficiency syndrome 11.1
34 acth-independent macronodular adrenal hyperplasia 11.1
35 chromosome xq26.3 duplication syndrome 11.1
36 hyperpituitarism 11.1
37 paroxysmal hemicrania 11.1
38 pituitary apoplexy 10.4
39 gangliocytoma 10.4
40 hypopituitarism 10.4
41 hyperprolactinemia 10.3
42 craniopharyngioma 10.3
43 multiple endocrine neoplasia 10.3
44 pituitary tumors 10.3
45 triple-receptor negative breast cancer 10.3 HOTAIR MALAT1
46 esophagus squamous cell carcinoma 10.3 HOTAIR MEG3
47 multiple endocrine neoplasia, type i 10.3
48 hypoxia 10.3
49 vulva squamous cell carcinoma 10.3 MALAT1 MEG3
50 mccune-albright syndrome 10.3

Graphical network of the top 20 diseases related to Pituitary Adenoma:



Diseases related to Pituitary Adenoma

Symptoms & Phenotypes for Pituitary Adenoma

Drugs & Therapeutics for Pituitary Adenoma

Drugs for Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 83150-76-9 383414 6400441
5
Pasireotide Approved Phase 4,Phase 2,Phase 3 396091-73-9 9941444
6
Metformin Approved Phase 4 657-24-9 14219 4091
7
Zinc Approved, Investigational Phase 4 7440-66-6
8
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 51110-01-1, 38916-34-6 53481605
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
11
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable 81409-90-7 54746
12 lanreotide Approved Phase 4,Phase 3 108736-35-2
13
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
14
Cefdinir Approved Phase 4 91832-40-5 6915944
15
leucovorin Approved Phase 4,Phase 1 58-05-9 6006 143
16
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
17
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
18
Cefazolin Approved Phase 4 25953-19-9 656510 33255
19
Sulfamethoxazole Approved Phase 4 723-46-6 5329
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
21
Lactitol Investigational Phase 4 585-86-4 3871
22 Hormones Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
24 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Not Applicable
25 glucocorticoids Phase 4,Phase 2,Not Applicable
26 Hydrocortisone-17-butyrate Phase 4,Not Applicable
27 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
28 Anesthetics Phase 4,Phase 1,Not Applicable
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
31 Cortisol succinate Phase 4,Phase 3,Phase 2,Not Applicable
32 Insulin, Globin Zinc Phase 4,Phase 2
33 insulin Phase 4,Phase 2
34 Liver Extracts Phase 4
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36
protease inhibitors Phase 4,Not Applicable
37 Sitagliptin Phosphate Phase 4
38 Incretins Phase 4
39 Hypoglycemic Agents Phase 4,Phase 2,Not Applicable
40 Dipeptidyl-Peptidase IV Inhibitors Phase 4
41 HIV Protease Inhibitors Phase 4,Not Applicable
42 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
43 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Dopamine agonists Phase 4,Phase 3,Phase 2,Not Applicable
46 Anti-Bacterial Agents Phase 4,Not Applicable
47 Antibiotics, Antitubercular Phase 4,Not Applicable
48 Angiopeptin Phase 4,Phase 3
49 cefuroxime axetil Phase 4
50 Renal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
3 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
4 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
5 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
6 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
7 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
8 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
9 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
10 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
11 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
12 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
13 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
14 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
15 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
16 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
17 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
18 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
19 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
20 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
21 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699;LCI699 matching placebo
22 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
23 Open-label Treatment in Cushing's Syndrome Not yet recruiting NCT03621280 Phase 3 Levoketoconazole
24 Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency Terminated NCT00630487 Phase 3 Placebo;Somatropin
25 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
26 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
27 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
28 Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Completed NCT01283542 Phase 2 Pasireotide LAR
29 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
30 An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly Completed NCT00171730 Phase 2 Pasireotide
31 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
32 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
33 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
34 Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy Recruiting NCT01849484 Phase 2
35 Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas Recruiting NCT01444209 Phase 2
36 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
37 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
38 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
39 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
40 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
41 Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease Not yet recruiting NCT03708900 Phase 2 LCI699
42 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
43 Treatment of Cushing's Disease With R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
44 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
45 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2 Pasireotide
46 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
47 Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Withdrawn NCT01203618 Phase 2 Farletuzumab
48 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Recruiting NCT02769533 Phase 1 OTL0038;Benadryl
49 Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT Recruiting NCT03404414 Phase 1 18F-FDG
50 Intraoperative Imaging of Pituitary Adenomas by OTL Active, not recruiting NCT02629549 Phase 1 OTL38

Search NIH Clinical Center for Pituitary Adenoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pituitary neoplasms

Genetic Tests for Pituitary Adenoma

Genetic tests related to Pituitary Adenoma:

# Genetic test Affiliating Genes
1 Pituitary Adenoma 29

Anatomical Context for Pituitary Adenoma

MalaCards organs/tissues related to Pituitary Adenoma:

41
Pituitary, Thyroid, Liver, Bone, Brain, Testes, Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Pituitary Adenoma:

19
The Pituitary Gl

Publications for Pituitary Adenoma

Articles related to Pituitary Adenoma:

(show top 50) (show all 1331)
# Title Authors Year
1
Inhibition of Notch signaling attenuates pituitary adenoma growth in Nude mice. ( 30121620 )
2019
2
Top 100 Most-Cited Articles on Pituitary Adenoma: A Bibliometric Analysis. ( 29870843 )
2018
3
Association of retinal nerve fibre layer thickness with quantitative magnetic resonance imaging data of the optic chiasm in pituitary adenoma patients. ( 29398198 )
2018
4
Clinical and pathological characteristics predicted the postoperative recurrence and progression of pituitary adenoma: a retrospective study with 10 years follow-up. ( 29981466 )
2018
5
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. ( 29143885 )
2018
6
Massive pleural and pericardial effusion due to hypothyroidism in a patient with a surgically treated thyroid-stimulating hormone-producing pituitary adenoma. ( 29757110 )
2018
7
Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway. ( 29288766 )
2018
8
Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an <i>AIP</i> Mutation-Positive Family. ( 29849625 )
2018
9
Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. ( 29909598 )
2018
10
Spontaneous improvement of cutis verticis gyrata secondary to acromegaly following surgical treatment of pituitary adenoma. ( 29927514 )
2018
11
Caveolin-1 promotes pituitary adenoma cells migration and invasion by regulating the interaction between EGR1 and KLF5. ( 29309750 )
2018
12
MicroRNA-378 regulates cell proliferation and migration by repressing RNF31 in pituitary adenoma. ( 29399147 )
2018
13
Clinical outcomes of endoscopic versus microscopic trans-sphenoidal surgery for large pituitary adenoma. ( 29417847 )
2018
14
EVALUATION OF CARDIOVASCULAR RISK WITH ARTERIAL STIFFNESS IN PATIENTS WITH NON-FUNCTIONING PITUITARY ADENOMA. ( 29975581 )
2018
15
Primary meningeal melanocytoma in sellar region, simulating a nonfunctioning pituitary adenoma; a case report and literature review. ( 29382618 )
2018
16
The Predictive Value of Suprasellar Extension for Visual Function Evaluation in Chinese Patients with Nonfunctioning Pituitary Adenoma with Optic Chiasm Compression. ( 29857216 )
2018
17
Data of phosphoproteomic analysis of non-functioning pituitary adenoma. ( 29900237 )
2018
18
Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm. ( 29404245 )
2018
19
Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs. ( 29864631 )
2018
20
Perioperative serum cortisol levels in ACTH sufficient and ACTH deficient patients during transsphenoidal surgery of pituitary adenoma. ( 29968225 )
2018
21
A thyrotropin-secreting pituitary adenoma treated with radiosurgery: Long-term outcomes. ( 29426625 )
2018
22
Diabetes Insipidus following Endoscopic Transsphenoidal Surgery for Pituitary Adenoma. ( 29868315 )
2018
23
Universal Sellar Anatomical Reconstruction Using the Sellar Floor Flap after Endoscopic Pituitary Adenoma Surgery. ( 29436283 )
2018
24
Mortality in patients with non-functioning pituitary adenoma. ( 29344906 )
2018
25
Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma. ( 29955610 )
2018
26
TSH-STAINING PITUITARY ADENOMA: A RARE ENTITY WITH CHANGING FACETS. ( 29949433 )
2018
27
Evaluation of Complications and Costs During Overlapping Transsphenoidal Surgery in the Treatment of Pituitary Adenoma. ( 29897572 )
2018
28
The clinical value of the multi-channel PVEP and PERG in the diagnosis and management of the patient with pituitary adenoma: a case report. ( 29968203 )
2018
29
Postoperative growth hormone dynamics in clinically nonfunctioning pituitary adenoma. ( 29910227 )
2018
30
Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery. ( 29450811 )
2018
31
Case report of recurrent atrial fibrillation induced by thyrotropin-secreting pituitary adenoma with Graves' disease. ( 29901603 )
2018
32
Risk category system to identify pituitary adenoma patients with<i>AIP</i>mutations. ( 29440248 )
2018
33
Endoscopic Endonasal Resection of a Suprasellar Pituitary Adenoma Mimicking Tuberculum Sellae Meningioma in a Patient with an Intrasellar Persistent Trigeminal Artery. ( 29588905 )
2018
34
Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis Based on Patients Treated Using Contemporary Techniques. ( 29678524 )
2018
35
Combined effects of resveratrol and radiation in GH3 and TtT/GF pituitary adenoma cells. ( 29872948 )
2018
36
CantA_ syndrome with coexisting familial pituitary adenoma. ( 29327300 )
2018
37
Neurosurgical image: giant pituitary adenoma and multiple aneurysms. ( 29373931 )
2018
38
Nonfunctioning Pituitary Adenoma That Changed to a Functional Gonadotropinoma. ( 29854488 )
2018
39
Integration of Proteomics and Metabolomics Revealed Metabolite-Protein Networks in ACTH-Secreting Pituitary Adenoma. ( 30532734 )
2018
40
A machine learning approach to predict early outcomes after pituitary adenoma surgery. ( 30453460 )
2018
41
Volumetry in the Assessment of Pituitary Adenoma Resection: Endoscopy versus Microscopy. ( 30456022 )
2018
42
The relationship between phospho-p38, MMP-9, and MICA expression in pituitary adenomas demonstrates a new mechanism of pituitary adenoma immune escape. ( 30458325 )
2018
43
Super Giant GH-secreting pituitary adenoma in a young woman: from the ventricles to the nose. ( 30472284 )
2018
44
VALIDATION OF A CLINICOPATHOLOGICALSCORE FOR THE PREDICTION OF POST-SURGICAL EVOLUTION OF PITUITARY ADENOMA: RETROSPECTIVE ANALYSIS ON 566 PATIENTS FROM A TERTIARY CARE CENTRE. ( 30481158 )
2018
45
Pediatric silent corticotroph pituitary adenoma and role for proton therapy: case report. ( 30497138 )
2018
46
Genome-wide identification of lncRNAs and mRNAs differentially expressed in non-functioning pituitary adenoma and construction of a lncRNA-mRNA co-expression network. ( 30504132 )
2018
47
The application of nasoseptal "rescue" flap technique in endoscopic transsphenoidal pituitary adenoma resection. ( 30535967 )
2018
48
Role and mechanisms of a three-dimensional bioprinted microtissue model in promoting proliferation and invasion of growth-hormone-secreting pituitary adenoma cells. ( 30537696 )
2018
49
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. ( 30540568 )
2018
50
A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. ( 30542712 )
2018

Variations for Pituitary Adenoma

Copy number variations for Pituitary Adenoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 55796 11 55700000 65900000 Copy number Pituitary adenoma
2 58390 11 67250504 67258578 Amplification AIP Pituitary adenoma
3 64485 12 12870301 12875305 Amplification CDKN1B Pituitary adenoma

Expression for Pituitary Adenoma

Search GEO for disease gene expression data for Pituitary Adenoma.

Pathways for Pituitary Adenoma

Pathways related to Pituitary Adenoma according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 ErbB signaling pathway hsa04012
3 Cell cycle hsa04110
4 Apoptosis hsa04210
5 Insulin signaling pathway hsa04910

GO Terms for Pituitary Adenoma

Cellular components related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 MIR103A2 MIR128-1 MIR132 MIR136 MIR15A MIR16-1
2 micro-ribonucleoprotein complex GO:0035068 9.5 H19 MEG3 MIR103A2 MIR128-1 MIR132 MIR136

Biological processes related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.5 H19 MEG3 MIR103A2 MIR128-1 MIR132 MIR136
2 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.43 MIR132 MIRLET7F1
3 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.4 MIR15A MIR16-1
4 negative regulation of sprouting angiogenesis GO:1903671 9.37 MIR7-1 MIR7-3
5 miRNA mediated inhibition of translation GO:0035278 9.35 MIR103A2 MIR132 MIR15A MIR16-1 MIRLET7A1
6 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.32 MIR15A MIR16-1
7 positive regulation of endothelial cell apoptotic process GO:2000353 9.26 MIR132 MIR15A
8 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.16 MIR15A MIR16-1

Molecular functions related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR103A2 MIR128-1 MIR132 MIR149 MIR15A MIR16-1

Sources for Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....